|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
none reported
|
|
gptkbp:annual_report
|
available online
|
|
gptkbp:business_model
|
research and development driven
|
|
gptkbp:can_lead_to
|
gptkb:Imetelstat
|
|
gptkbp:ceo
|
gptkb:Dr._John_Scarlett
|
|
gptkbp:clinical_trial
|
ongoing
Phase 2
published in peer-reviewed journals
multiple sites across the US
Phase 3 planned
reported in conferences
|
|
gptkbp:collaborations
|
academic institutions
|
|
gptkbp:community_engagement
|
active in local initiatives
|
|
gptkbp:competitors
|
other biotech firms
|
|
gptkbp:employees
|
approximately 50
|
|
gptkbp:financial_reports
|
quarterly updates available
|
|
gptkbp:focus
|
innovative therapies
telomerase-based therapeutics
|
|
gptkbp:founded
|
gptkb:1990
|
|
gptkbp:founder
|
gptkb:Dr._John_Scarlett
|
|
gptkbp:funding
|
secured from various sources
|
|
gptkbp:future_plans
|
expand into new markets
|
|
gptkbp:has_advisory_board
|
comprised of industry experts
|
|
gptkbp:headquarters
|
gptkb:Menlo_Park,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Geron Corporation
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:instruction_set
|
multiple drug candidates
|
|
gptkbp:invention
|
multiple granted patents
|
|
gptkbp:investment
|
institutional and retail investors
transparent communication
venture capital funding
frequent communications.
|
|
gptkbp:investment_focus
|
oncology
|
|
gptkbp:investment_strategy
|
volatile
|
|
gptkbp:investor_meetings
|
regularly scheduled
|
|
gptkbp:is_a_platform_for
|
telomerase inhibition
|
|
gptkbp:key_people
|
gptkb:Dr._John_Scarlett
|
|
gptkbp:leadership
|
experienced management team
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:market_cap
|
$300 million (2023)
|
|
gptkbp:marketing_strategy
|
collaborative partnerships
|
|
gptkbp:net_income
|
-$20 million (2022)
|
|
gptkbp:notable_products
|
gptkb:Imetelstat
|
|
gptkbp:partnership
|
research institutions
|
|
gptkbp:partnerships
|
various pharmaceutical companies
|
|
gptkbp:product
|
ongoing
|
|
gptkbp:publications
|
numerous articles published
|
|
gptkbp:regulatory_compliance
|
submitted to FDA
pending for Imetelstat
|
|
gptkbp:research_and_development
|
significant investment
|
|
gptkbp:research_areas
|
hematologic malignancies
|
|
gptkbp:research_focus
|
gptkb:cancer_treatment
|
|
gptkbp:revenue
|
$10 million (2022)
|
|
gptkbp:social_responsibility
|
commitment to ethical practices
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
GERN
|
|
gptkbp:stock_volatility
|
high
|
|
gptkbp:strategic_goals
|
expand product pipeline
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.geron.com
|
|
gptkbp:bfsParent
|
gptkb:Imetelstat
|
|
gptkbp:bfsLayer
|
6
|